Amarin (NASDAQ:AMRN – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Wednesday, March 12th. Analysts expect Amarin to post earnings of ($0.06) per ...

Operator Welcome to Amarin Corporation's conference call to discuss its fourth-quarter and full-year 2024 business update and ...

And Steve Ketchum, Amarin's Executive Vice President, President of R&D and Chief Scientific Officer will provide an update on recent and upcoming VASCEPA/VAZKEPA research. And at the end of the ...

Leading up to and during those negotiations, you'll likely hear the terms "salary cap" and "cap space" used by analysts to describe whether or not teams are in the running for specific players.

IPE, which is the active ingredient in vascepa, significantly reduced the primary composite endpoint of cardiovascular events by 34% among patients with very well-controlled LDL-C. Elevated LDL-C ...

The company maintains a strong cash position with $294 million and no debt. Patent protection for Vascepa in Europe extended to 2039, securing future market opportunities. Amarin’s overall ...

mainly due to pricing pressure from U.S. generics targeting its heart disease therapy Vascepa/Vazkepa. As for the bottom line, AMRN reported an adjusted basic and diluted loss per share of $0.02 ...